Journal of Clinical Endocrinology & Metabolism, Vol 80, 3617-3620, Copyright © 1995 by Endocrine Society

ARTICLES

11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome

PM Stewart, BR Walker, G Holder, D O'Halloran and CH Shackleton
Department of Medicine, Queen Elizabeth Hospital, Birmingham, United Kingdom.

A characteristic feature of the ectopic ACTH syndrome is a state of mineralocorticoid excess, although the etiology remains obscure. Some forms of endocrine hypertension, such as licorice ingestion, have been explained by cortisol acting as a mineralocorticoid in the setting of inhibition or deficiency of 11 beta-hydroxysteroid dehydrogenase (11 beta HSD). This enzyme is responsible for the conversion of cortisol (F) to hormonally inactive cortisone, and its activity in vivo can be inferred from the ratio of the urinary excretion of tetrahydrocortisol (THF) and its isomer (5 alpha THF) to tetrahydrocortisone. Twenty-two patients with Cushing's syndrome (11 pituitary dependent, 9 ectopic, and 2 adrenal adenomas) and 13 controls were studied. Compared to controls. Cushing's patients had a significant increase (P < 0.001) in the excretion of all principal metabolites of F, secondary to a 5- to 6- fold increase in the cortisol secretion rate [median, 34.0 (range, 13.3- 327) mg/day in Cushing's vs. 6.1 (range, 2.5-10.3) mg/day in controls]. The THF plus 5 alpha THF/tetrahydrocortisone ratio was significantly increased in Cushing's syndrome regardless of etiology [mean, 1.81 (range, 1.09-9.99) in Cushing's vs. 0.81 (range, 0.51-1.47) in controls; P < 0.001), indicative of defective 11 beta HSD activity. Furthermore, compared to patients with pituitary-dependent Cushing's, this ratio was significantly higher in patients with the ectopic ACTH syndrome (4.12 vs. 1.49; P < 0.01) and was inversely correlated with serum potassium levels (r = -0.57; P = 0.01; n = 22). One explanation for the mineralocorticoid excess state of the ectopic ACTH syndrome appears to be that cortisol gains inappropriate access to the mineralocorticoid receptor through failure of its normal metabolism by 11 beta HSD. The reason for the defective 11 beta HSD activity is unclear, but it may be secondary to substrate saturation, inhibition by other adrenal steroids, or product inhibition.

This article has been cited by other articles:

				M. S. Cooper and P. M. Stewart Adrenal Insufficiency in Critical Illness J Intensive Care Med, November 1, 2007; 22(6): 348 - 362. [Abstract] [PDF]

				L. R. Salgado, M. C. B V. Fragoso, M. Knoepfelmacher, M. C. Machado, S. Domenice, M. A. A. Pereira, and B. B. de Mendonca Ectopic ACTH syndrome: our experience with 25 cases. Eur. J. Endocrinol., November 1, 2006; 155(5): 725 - 733. [Abstract] [Full Text] [PDF]

				E. J. Lichtarowicz-Krynska, T. J. Cole, C. Camacho-H""bner, J. Britto, M. Levin, N. Klein, and A. Aynsley-Green Circulating Aldosterone Levels Are Unexpectedly Low in Children with Acute Meningococcal Disease J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1410 - 1414. [Abstract] [Full Text] [PDF]

				G. Arnaldi, T. Mancini, B. Kola, G. Appolloni, S. Freddi, C. Concettoni, I. Bearzi, A. Masini, M. Boscaro, and F. Mantero Cyclical Cushing's Syndrome in a Patient with a Bronchial Neuroendocrine Tumor (Typical Carcinoid) Expressing Ghrelin and Growth Hormone Secretagogue Receptors J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5834 - 5840. [Abstract] [Full Text] [PDF]

				M. Quinkler and P. M. Stewart Hypertension and the Cortisol-Cortisone Shuttle J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2384 - 2392. [Abstract] [Full Text] [PDF]

				D. J. TORPY, N. MULLEN, I. ILIAS, and L. K. NIEMAN Association of Hypertension and Hypokalemia with Cushing's Syndrome Caused by Ectopic ACTH Secretion: A Series of 58 Cases Ann. N.Y. Acad. Sci., September 1, 2002; 970(1): 134 - 144. [Abstract] [Full Text] [PDF]

				J. W. Tomlinson, N. Draper, J. Mackie, A. P. Johnson, G. Holder, P. Wood, and P. M. Stewart Absence of Cushingoid Phenotype in a Patient with Cushing's Disease due to Defective Cortisone to Cortisol Conversion J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 57 - 62. [Abstract] [Full Text] [PDF]

				J. W. Chu, D. F. Matthias, J. Belanoff, A. Schatzberg, A. R. Hoffman, and D. Feldman Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU 486) J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3568 - 3573. [Abstract] [Full Text] [PDF]

				R. Alzamora, L. Michea, and E. T. Marusic Role of 11{beta}-Hydroxysteroid Dehydrogenase in Nongenomic Aldosterone Effects in Human Arteries Hypertension, May 1, 2000; 35(5): 1099 - 1104. [Abstract] [Full Text] [PDF]

				J. Newell-Price, P. Trainer, M. Besser, and A. Grossman The Diagnosis and Differential Diagnosis of Cushing's Syndrome and Pseudo-Cushing's States Endocr. Rev., October 1, 1998; 19(5): 647 - 672. [Abstract] [Full Text]

				S. H.M. van Uum, A. R.M.M. Hermus, P. Smits, T. Thien, and J. W.M. Lenders The role of 11{beta}-hydroxysteroid dehydrogenase in the pathogenesis of hypertension Cardiovasc Res, April 1, 1998; 38(1): 16 - 24. [Abstract] [Full Text] [PDF]

				G. Morineau, A. Boudi, A. Barka, M. Gourmelen, F. Degeilh, N. Hardy, A. Al-Halnak, H. Soliman, J. P. Gosling, R. Julien, et al. Radioimmunoassay of cortisone in serum, urine, and saliva to assess the status of the cortisol–cortisone shuttle Clin. Chem., August 1, 1997; 43(8): 1397 - 1407. [Abstract] [Full Text] [PDF]

				M. Shimojo, M. L. Ricketts, M. D. Petrelli, P. Moradi, G. D. Johnson, A. R. Bradwell, M. Hewison, A. J. Howie, and P. M. Stewart Immunodetection of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 in Human Mineralocorticoid Target Tissues: Evidence for Nuclear Localization Endocrinology, March 1, 1997; 138(3): 1305 - 1311. [Abstract] [Full Text] [PDF]